This financing round will enable Xeltis to scale production and advance the commercialisation of aXess, its innovative vascular access conduit for haemodialysis, following positive EU pivotal trial results. Market approval in Europe and US pre-market approval are expected in 2026.
We acted as Dutch and Swiss counsel to the EIB, drafting, negotiating and implementing the transaction documentation across both jurisdictions. Our team is proud to be part of EIB’s investment strategy supporting medtech innovation.
To discuss how we can be of value in your future projects, please contact one of our team members below.
